About Pecanex-like protein 2
Pecanex-like protein 2 (PCNX2) is a protein
from Homo sapiens identified by UniProt accession
A6NKB5, 2137 residues long.
MolForge cross-references it against 0 known binders and
91 disease associations.
Target properties
| Protein name | Pecanex-like protein 2 |
| UniProt accession | A6NKB5 |
| Gene | PCNX2 |
| Organism | Homo sapiens |
| Length | 2137 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (91)
Diseases linked to this target (Open Targets).
- thyroid carcinoma · score 0.31
- early-onset non-syndromic cataract · score 0.10
- hereditary hyperferritinemia with congenital cataracts · score 0.08
- isolated ectopia lentis · score 0.08
- Posterior polar cataract · score 0.08
- Total congenital cataract · score 0.07
- Cataract-microcornea syndrome · score 0.07
- cataract 13 with adult I phenotype · score 0.07
- cataract 38 · score 0.07
- Anterior polar cataract · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NKB5-F1 | alphafold | PREDICTED | 56.62 | — |
Amino-acid sequence (2137 residues)
MVSQVLQLLR QGVWAALTGG WYHDPEQSKF TNSCHLYLWL FLLLLPLALH LAFPPNAIIV FFYCSAVTIF FTIIKLVSYR LHLMFDKGEV IQQKPSRKEE KPNKDKEAKG EHITNHRNPS NNRQIHNGKK EEASRNLSTP PLRCSSRGQS ITSHHSSGPL ELSAQETVED LKGVILLEDH PIAPVSSTSP GIKVESLPAS QAHMLETTTK SVIPVKPVAT ETLINGKGKE RGGKGQPPLR HRSEGGLVDK GPLKKLPHLS LSQYDLLETD VSFQPWGSEN SVLIPEPVSC PRGSIRERVQ SKSPQDSLSS SCPQCDTIVA KPVEEPADTS CQVDTSCQGD LPLHQEVDSS DSEVAVTLID TSQPGDPLSL HEPIKIVITM SSTPNSMTDL ESSLHLRVVG TEKTSVKSDA EPTNPGAAGS PNAEQISIPV ITLDLPEGGG GGVPCPEGNG SERTPERLKT RVSTNQCSGY GSGEGGNAIK DHSSSSREPW ESVSRLTPDT GSESKVGKEG QTNLDPSSCK SSHEKRHARV LSVDSGTDVF LSKSSAEIVN DTEKTMPTSK SDLEAKEGQM PNESNFLEFV SLLESINTSK MTASSQLNGS AEQNEESGLL RDNCSQEKKE EILENEKPSG HSSKQGKPDL QSQDHTSTGP ACTQPAKTTA FFQGNRQRQI IYRVTSQQDS SVLQVISGPE TSVQEEISVD AMHVFIDEHG EIRSCYLKSG NQKEGPLQPL PSNNDCLSQA REMQVSSSST TTSESQDPSS GDPAVSALQQ QLLLMVARRT QSETPRHVSQ DLEASSCSST QGKFNREQFY KFIIFPGKWI KVWYDRLTLL ALLDRTEDIK ENVLAILLIV LVSLLGFLTL SQGFCKDMWV LLFCLVMASC QYSLLKSVQP DPASPIHGHN QIITYSRPIY FCVLCGLILL LDTGAKARHP PSYVVYGLKL FSPVFLQSAR DYLIVFLYCF PAISLLGLFP QINTFCTYLL EQIDMLFFGG SAVSGITSAV YSVARSVLAA ALLHAVCFSA VKEPWSMQHI PALFSAFCGL LVALSYHLSR QSSDPSVLMS FIQCRLFPKF LHQNLAESAA DPLPKKMKDS VTDVLKWDLI VCAVVAVLSF AVSASTVFLS LRPFLSIVLF ALAGAVGFVT HYVLPQLRKH HPWMWISHPI LKNKEYHQRE VRDVAHLMWF ERLYVWLQCF EKYILYPALI LNALTIDAFL ISNHRRLGTH WDIFLMIIAG MKLLRTSFCN PVYQFINLSF TVIFFHFDYK DISESFLLDF FMVSILFSKL GDLLHKLQFV LTYVAPWQMA WGSSFHVFAQ LFAIPHSAML FFQTIATSIF STPLSPFLGS VIFITSYVRP VKFWEKNYNT RRVDNSNTRL AVQIERDPGN DDNNLNSIFY EHLTRTLQES LCGDLVLGRW GNYSSGDCFI LASDDLNAFV HLIEIGNGLV TFQLRGLEFR GTYCQQREVE AIMEGDEEDR GCCCCKPGHL PHLLSCNAAF HLRWLTWEIT QTQYILEGYS ILDNNAATML QVFDLRRILI RYYIKSIIYY MVTSPKLLSW IKNESLLKSL QPFAKWHYIE RDLAMFNINI DDDYVPCLQG ITRASFCNVY LEWIQHCARK RQEPSTTLDS DEDSPLVTLS FALCTLGRRA LGTAAHNMAI SLDSFLYGLH VLFKGDFRIT ARDEWVFADM DLLHKVVAPA IRMSLKLHQD QFTCPDEYED PAVLYEAIQS FEKKVVICHE GDPAWRGAVL SNKEELLTLR HVVDEGADEY KVIMLHRSFL SFKVIKVNKE CVRGLWAGQQ QELIFLRNRN PERGSIQNNK QVLRNLINSS CDQPLGYPMY VSPLTTSYLG THRQLKNIWG GPITLDRIRT WFWTKWVRMR KDCNARQHSG GNIEDVDGGG APTTGGNNAP SGGSQESSAE QPRKGGAQHG VSSCEGTQRT GRRKGRSQSV QAHSALSQRP PMLSSSGPIL ESRQTFLQTS TSVHELAQRL SGSRLSLHAS ATSLHSQPPP VTTTGHLSVR ERAEALIRSS LGSSTSSTLS FLFGKRSFSS ALVISGLSAA EGGNTSDTQS SSSVNIVMGP SARAASQATR HLSEPCEPPD ATEQGQLHDR CLAEAVADTL GVVCRRASQE DMGLDDTASQ QSVSDEQ
Explore Pecanex-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets